Description: BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Home Page: www.biolinerx.com
BLRX Technical Analysis
Modi’in Technology Park
Hevel Modi'in,
7177871
Israel
Phone:
972 8 642 9100
Officers
| Name | Title |
|---|---|
| Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Exec. Officer |
| Ms. Mali Zeevi CPA, CPA | Chief Financial Officer |
| Dr. Ella Sorani | Chief Devel. Officer |
| Mr. John Lacey | Head of Corp. Communications & Investor Relations |
| Advocate Norman Kotler | Internal Enforcement Officer, Gen. Counsel and Corp. Sec. |
| Ms. Liron Shemesh-Darvish M.B.A., Ph.D. | Sr. Director & Head of Preclinical Devel. |
| Ms. Jael Birenberg M.Sc. | Sr. Director & Head of RA, QA and PhV |
| Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor |
| Ms. Holly W. May M.B.A. | Pres of BioLineRx USA |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7645 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2011-07-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |